|
1
|
Liao R, Jain M, Teller P, Connors LH, Ngoy
S, Skinner M, Falk RH and Apstein CS: Infusion of light chains from
patients with cardiac amyloidosis causes diastolic dysfunction in
isolated mouse hearts. Circulation. 104:1594–1597. 2001.PubMed/NCBI
|
|
2
|
Guan J, Mishra S, Shi J, Plovie E, Qiu Y,
Cao X, Gianni D, Jiang B, Del Monte F, Connors LH, et al:
Stanniocalcin1 is a key mediator of amyloidogenic light chain
induced cardiotoxicity. Basic Res Cardiol. 108(378)2013.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Aimo A, Buda G, Fontana M, Barison A,
Vergaro G, Emdin M and Merlini G: Therapies for cardiac light chain
amyloidosis: An update. Int J Cardiol. 271:152–160. 2018.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Shi J, Guan J, Jiang B, Brenner DA, Del
Monte F, Ward JE, Connors LH, Sawyer DB, Semigran MJ, Macgillivray
TE, et al: Amyloidogenic light chains induce cardiomyocyte
contractile dysfunction and apoptosis via a non-canonical p38alpha
MAPK pathway. Proc Natl Acad Sci USA. 107:4188–4193.
2010.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Tuzovic M, Yang EH, Baas AS, Depasquale
EC, Deng MC, Cruz D and Vorobiof G: Cardiac amyloidosis: Diagnosis
and treatment strategies. Curr Oncol Rep. 19(46)2017.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Tanaka K, Essick EE, Doros G, Tanriverdi
K, Connors LH, Seldin DC and Sam F: Circulating matrix
metalloproteinases and tissue inhibitors of metalloproteinases in
cardiac amyloidosis. J Am Heart Assoc. 2(e005868)2013.PubMed/NCBI View Article : Google Scholar
|
|
7
|
WRITING COMMITTEE MEMBERS. Yancy CW,
Jessup M, Bozkurt B, Butler J, Casey DE Jr, Drazner MH, Fonarow GC,
Geraci SA, Horwich T, et al: 2013 ACCF/AHA guideline for the
management of heart failure: A report of the American College of
Cardiology Foundation/American Heart Association Task Force on
practice guidelines. Circulation. 128:e240–e327. 2013.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Lavatelli F, Imperlini E, Orru S, Rognoni
P, Sarnataro D, Palladini G, Malpasso G, Soriano ME, Di Fonzo A,
Valentini V, et al: Novel mitochondrial protein interactors of
immunoglobulin light chains causing heart amyloidosis. FASEB J.
29:4614–4628. 2015.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Brenner DA, Jain M, Pimentel DR, Wang B,
Connors LH, Skinner M, Apstein CS and Liao R: Human amyloidogenic
light chains directly impair cardiomyocyte function through an
increase in cellular oxidant stress. Circ Res. 94:1008–1010.
2004.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Imperlini E, Gnecchi M, Rognoni P, Sabidò
E, Ciuffreda MC, Palladini G, Espadas G, Mancuso FM, Bozzola M,
Malpasso G, et al: Proteotoxicity in cardiac amyloidosis:
Amyloidogenic light chains affect the levels of intracellular
proteins in human heart cells. Sci Rep. 7(15661)2017.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Guan J, Mishra S, Qiu Y, Shi J, Trudeau K,
Las G, Liesa M, Shirihai OS, Connors LH, Seldin DC, et al:
Lysosomal dysfunction and impaired autophagy underlie the
pathogenesis of amyloidogenic light chain-mediated cardiotoxicity.
EMBO Mol Med. 6:1493–1507. 2014.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Pattison JS and Robbins J: Protein
misfolding and cardiac disease: Establishing cause and effect.
Autophagy. 4:821–823. 2008.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Edwards HV, Cameron RT and Baillie GS: The
emerging role of HSP20 as a multifunctional protective agent. Cell
Signal. 23:1447–1454. 2011.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Sikkink LA and Ramirez-Alvarado M:
Cytotoxicity of amyloidogenic immunoglobulin light chains in cell
culture. Cell Death Dis. 1(e98)2010.PubMed/NCBI View Article : Google Scholar
|
|
15
|
McLaughlin RW, De Stigter JK, Sikkink LA,
Baden EM and Ramirez-Alvarado M: The effects of sodium sulfate,
glycosaminoglycans, and Congo red on the structure, stability, and
amyloid formation of an immunoglobulin light-chain protein. Protein
Sci. 15:1710–1722. 2006.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Baden EM, Owen BA, Peterson FC, Volkman
BF, Ramirez-Alvarado M and Thompson JR: Altered dimer interface
decreases stability in an amyloidogenic protein. J Biol Chem.
283:15853–15860. 2008.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Louch WE, Sheehan KA and Wolska BM:
Methods in cardiomyocyte isolation, culture, and gene transfer. J
Mol Cell Cardiol. 51:288–298. 2011.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Audic S and Claverie JM: The significance
of digital gene expression profiles. Genome Res. 7:986–995.
1997.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408.
2001.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Danilewicz M and Wagrowska-Danilewicz M:
Immunohistochemical analysis of transforming growth factor beta-1
in AA and AL renal amyloidosis. Pol J Pathol. 57:193–198.
2006.PubMed/NCBI
|
|
21
|
Weiss R, Lifshitz V and Frenkel D: TGF-β1
affects endothelial cell interaction with macrophages and T cells
leading to the development of cerebrovascular amyloidosis. Brain
Behav Immun. 25:1017–1024. 2011.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Lam HB, Yeh CH, Cheng KC, Hsu CT and Cheng
JT: Effect of cholinergic denervation on hepatic fibrosis induced
by carbon tetrachloride in rats. Neurosci Lett. 438:90–95.
2008.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Adams SL, Benayoun L, Tilton K, Mellott
TJ, Seshadri S, Blusztajn JK and Delalle I: Immunohistochemical
analysis of activin receptor-like kinase 1 (ACVRL1/ALK1) expression
in the rat and human hippocampus: Decline in CA3 during progression
of Alzheimer’s disease. J Alzheimers Dis. 63:1433–1443.
2018.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Papadopoulos P, Tong XK, Imboden H and
Hamel E: Losartan improves cerebrovascular function in a mouse
model of Alzheimer’s disease with combined overproduction of
amyloid-beta and transforming growth factor-β1. J Cereb Blood Flow
Metab. 37:1959–1970. 2017.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Dobaczewski M, Chen W and Frangogiannis
NG: Transforming growth factor (TGF)-β signaling in cardiac
remodeling. J Mol Cell Cardiol. 51:600–606. 2011.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Villar AV, García R, Llano M, Cobo M,
Merino D, Lantero A, Tramullas M, Hurlé JM, Hurlé MA and Nistal JF:
BAMBI (BMP and activin membrane-bound inhibitor) protects the
murine heart from pressure-overload biomechanical stress by
restraining TGF-β signaling. Biochim Biophys Acta. 1832:323–335.
2013.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Wu F, Yao H, Bader A, Dong F, Zhu F, Wu N,
Wang B, Li H, Brockmeyer NH and Altmeyer P: Decorin gene transfer
inhibited the expression of TGFbeta1 and ECM in rat mesangial
cells. Eur J Med Res. 12:360–368. 2007.PubMed/NCBI
|
|
28
|
Lu J, Sun B, Huo R, Wang YC, Yang D, Xing
Y, Xiao XL, Xie X and Dong DL: Bone morphogenetic protein-2
antagonizes bone morphogenetic protein-4 induced cardiomyocyte
hypertrophy and apoptosis. J Cell Physiol. 229:1503–1510.
2014.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Wu X, Sagave J, Rutkovskiy A, Haugen F,
Baysa A, Nygård S, Czibik G, Dahl CP, Gullestad L, Vaage J and
Valen G: Expression of bone morphogenetic protein 4 and its
receptors in the remodeling heart. Life Sci. 97:145–154.
2014.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Banach J, Gilewski W, Slomka A, Buszko K,
Błażejewski J, Karasek D, Rogowicz D, Żekanowska E and Sinkiewicz
W: Bone morphogenetic protein 6-a possible new player in
pathophysiology of heart failure. Clin Exp Pharmacol Physiol.
43:1247–1250. 2016.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Knittel T, Fellmer P, Muller L and
Ramadori G: Bone morphogenetic protein-6 is expressed in
nonparenchymal liver cells and upregulated by transforming growth
factor-beta 1. Exp Cell Res. 232:263–269. 1997.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Yano R, Golbar HM, Izawa T, Sawamoto O,
Kuwamura M and Yamate J: Participation of bone morphogenetic
protein (BMP)-6 and osteopontin in cisplatin (CDDP)-induced rat
renal fibrosis. Exp Toxicol Pathol. 67:99–107. 2015.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Fattahi MJ and Mirshafiey A: Positive and
negative effects of prostaglandins in Alzheimer’s disease.
Psychiatry Clin Neurosci. 68:50–60. 2014.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Bitto A, Giuliani D, Pallio G, Irrera N,
Vandini E, Canalini F, Zaffe D, Ottani A, Minutoli L, Rinaldi M, et
al: Effects of COX1-2/5-LOX blockade in Alzheimer transgenic
3xTg-AD mice. Inflamm Res. 66:389–398. 2017.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Riese DJ II and Cullum RL: Epiregul in:
Roles in normal physiology and cancer. Semin Cell Dev Biol.
28:49–56. 2014.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Singh B, Carpenter G and Coffey RJ: EGF
receptor ligands: Recent advances. F1000Res.
5(F1000)2016.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Zhang H, Zhang L, Zhou D, He X, Wang D,
Pan H, Zhang X, Mei Y, Qian Q, Zheng T, et al: Ablating ErbB4 in PV
neurons attenuates synaptic and cognitive deficits in an animal
model of Alzheimer’s disease. Neurobiol Dis. 106:171–180.
2017.PubMed/NCBI View Article : Google Scholar
|
|
38
|
White SK, Sado DM, Flett AS and Moon JC:
Characterising the myocardial interstitial space: The clinical
relevance of non-invasive imaging. Heart. 98:773–779.
2012.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Du H, Pang M, Hou X, Yuan S and Sun L:
PLOD2 in cancer research. Biomed Pharmacother. 90:670–676.
2017.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Innocente SA, Abrahamson JL, Cogswell JP
and Lee JM: p53 regulates a G2 checkpoint through cyclin B1. Proc
Natl Acad Sci USA. 96:2147–2152. 1999.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Milton NG: The amyloid-beta peptide binds
to cyclin B1 and increases human cyclin-dependent kinase-1
activity. Neurosci Lett. 322:131–133. 2002.PubMed/NCBI View Article : Google Scholar
|
|
42
|
da Silva Filho MI, Försti A, Weinhold N,
Meziane I, Campo C, Huhn S, Nickel J, Hoffmann P, Nöthen MM, Jöckel
KH, et al: Genome-wide association study of immunoglobulin light
chain amyloidosis in three patient cohorts: Comparison with
myeloma. Leukemia. 31:1735–1742. 2017.PubMed/NCBI View Article : Google Scholar
|
